Literature DB >> 29521828

Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials.

Mitsuro Kanda1, Koji Oba2, Toru Aoyama3, Kosuke Kashiwabara2, Shuhei Mayanagi4, Hiromichi Maeda5, Michitaka Honda6, Chikuma Hamada7, Sotaro Sadahiro8, Junichi Sakamoto9,10, Shigetoyo Saji10, Takaki Yoshikawa11.   

Abstract

BACKGROUND: Although colorectal cancer comprises several histological subtypes, the influences of histological subtypes on disease progression and treatment responses remain controversial.
OBJECTIVE: We sought to evaluate the prognostic relevance of mucinous and poorly differentiated histological subtypes of colorectal cancer by the propensity score weighting analysis of prospectively collected data from multi-institute phase III trials.
DESIGN: Independent patient data analysis of a pooled database from 3 phase III trials was performed. SETTINGS: An integrated database of 3 multicenter prospective clinical trials (the Japanese Foundation for Multidisciplinary Treatment of Cancer 7, 15, and 33) was the source of study data.
INTERVENTIONS: Surgery alone or postoperative adjuvant chemotherapy was offered in patients with resectable colorectal cancer. MAIN OUTCOME MEASURES: To balance essential variables more strictly for the comparison analyses, propensity score weighting was conducted with the use of a multinomial logistic regression model. We evaluated the clinical signatures of mucinous and poorly differentiated subtypes with regard to postoperative survival, recurrence, and chemosensitivity.
RESULTS: Of 5489 patients, 136 (2.5%) and 155 (2.8%) were pathologically diagnosed with poorly differentiated and mucinous subtypes. The poorly differentiated subtypes were associated with a poorer prognosis than the "others" group (HR, 1.69; 95% CI, 1.00-2.87; p = 0.051), particularly in the patient subgroup of adjuvant chemotherapy (HR, 2.16). Although the mucinous subtype had a marginal prognostic impact among patients with stage I to III colorectal cancer (HR, 1.33; 95% CI, 0.90-1.96), it was found to be an independent prognostic factor in the subpopulation of patients with stage II disease, being associated with a higher prevalence of peritoneal recurrence. LIMITATIONS: The treatment regimens of postoperative chemotherapy are now somewhat outdated.
CONCLUSIONS: Both mucinous and poorly differentiated subtypes have distinct clinical characteristics. Patients with the mucinous subtype require special attention during follow-up, even for stage II disease, because of the risk of peritoneal or local recurrence. See Video Abstract at http://links.lww.com/DCR/A531.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29521828     DOI: 10.1097/DCR.0000000000001022

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  7 in total

1.  Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

Authors:  Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yoshito Komatsu; Taroh Satoh; Masahiro Goto; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Naruhito Takenaka; Tadashi Hirooka; Kenichi Sugihara
Journal:  Glob Health Med       Date:  2020-08-31

2.  Establishment and validation of a novel nomogram incorporating clinicopathological parameters into the TNM staging system to predict prognosis for stage II colorectal cancer.

Authors:  Shaobo Mo; Zheng Zhou; Long Zhang; Sanjun Cai; Junjie Peng; Yaqi Li; Xiang Hu; Xiaoji Ma
Journal:  Cancer Cell Int       Date:  2020-07-06       Impact factor: 5.722

Review 3.  Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.

Authors:  An Huang; Yong Yang; Jing-Yi Shi; Yu-Kun Li; Jing-Xuan Xu; Yu Cheng; Jin Gu
Journal:  World J Gastrointest Surg       Date:  2021-12-27

4.  Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study.

Authors:  Chuanwang Yan; Hui Yang; Lili Chen; Ran Liu; Wei Shang; Wenguang Yuan; Fei Yang; Qing Sun; Lijian Xia
Journal:  BMC Cancer       Date:  2021-12-01       Impact factor: 4.430

5.  Impact of histological subtype on prognosis in stage IV colorectal cancer: A population-based cohort study.

Authors:  Teppei Miyakawa; Hidetaka Kawamura; Michitaka Honda; Yoshinao Takano; Shunji Kinuta; Takahiro Kamiga; Shigeru Yamazaki; Atsushi Muto; Satoru Shiraso; Naoyuki Yamashita; Toshiyasu Iwao; Koji Kono; Shinichi Konno
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

6.  Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.

Authors:  Gerardo Rosati; Fabio Galli; Maurizio Cantore; Francesca Bergamo; Maria Banzi; Maria Giulia Zampino; Rodolfo Mattioli; Giovanni Gerardo Cardellino; Monica Ronzoni; Maria Di Bartolomeo; Stefano Tamberi; Paolo Marchetti; Lorenza Rimassa; Domenico Corsi; Anna Maria Bochicchio; Fabrizio Artioli; Roberto Labianca; Francesca Galli; Eliana Rulli; Domenico Bilancia; Giacomo Bregni
Journal:  Oncologist       Date:  2020-01-13

7.  Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.

Authors:  Shaobo Mo; Xiaoji Ma; Yaqi Li; Long Zhang; Ting Hou; Han Han-Zhang; Juanjuan Qian; Sanjun Cai; Dan Huang; Junjie Peng
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.